Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PALB2 |
| Variant | P1009Lfs*6 |
| Impact List | frameshift |
| Protein Effect | loss of function |
| Gene Variant Descriptions | PALB2 P1009Lfs*6 indicates a shift in the reading frame starting at amino acid 1009 and terminating 6 residues downstream causing a premature truncation of the 1186 amino acid Palb2 protein (UniProt.org). P1009Lfs*6 confers a loss of function to the Palb2 protein as demonstrated by decreased protein stability and impaired homology-directed DNA repair activity compared to wild-type in cultured cells lacking Tp53 (PMID: 31757951). |
| Associated Drug Resistance | |
| Category Variants Paths |
PALB2 mutant PALB2 inact mut PALB2 P1009Lfs*6 |
| Transcript | NM_024675.4 |
| gDNA | chr16:g.23621453delG |
| cDNA | c.3026delC |
| Protein | p.P1009Lfs*6 |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_017023673 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| NM_001407299.1 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| NM_001407301.1 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| XM_017023673.2 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| XM_017023672.2 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| NM_024675.3 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| NM_024675.4 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| XM_017023672 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| NM_024675 | chr16:g.23621453delG | c.3026delC | p.P1009Lfs*6 | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 P1009Lfs*6 | Advanced Solid Tumor | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) resulted in decreased survival of TP53-knockout cells expressing PALB2 P1009Lfs*6 in culture (PMID: 31757951). | 31757951 |